Table 1.
First Author (Published Year) [Ref.] | Type of Study | Clinical Scenario | Type of Strain Used | Number of Patients in Each Group/Arm PE (+/− Other) Control | Main Results (Regarding PE-Related Findings) | |
---|---|---|---|---|---|---|
Kjaergaard et al. (2004) [21] | Prospective, consecutive patients | Sub-massive PE before and after thrombolysis and at 2 months follow-up | RVLS of the RV free wall | 3 | − | Middle part of RV-FW had low or positive strain that normalized after thrombolysis (apical and basal segments had unaffected strain) |
Park et al. (2007) [22] | Prospective, non-consecutive patients | PE before and after treatment (anticoagulation +/− thrombolysis) | PSS of the RV free wall | 24 | − | PSS of middle and apex part of RV-FW were impaired at the baseline and both improved after treatment (changes were more pronounced in the middle part) |
Sugiura et al. (2009) [23] | Prospective, non-consecutive patients | Massive or sub-massive PE before and after primary treatment Ɨ vs. control group (age- and sex-matched healthy subjects) | Global and regional RV PSS | 23 | 23 |
|
Park et al. (2010) [24] | Retrospective, non-consecutive | Acute CP due to massive PE vs. patients with chronic CP due to severe COPD | Regional RV PSS | 24 (28 COPD) | - |
|
Takamura et al. (2011) [25] | Prospective, consecutive patients | Massive or sub-massive PE before and after primary treatment Ɨ vs. control group (age- and sex-matched healthy subjects) | Global and regional LV PSS in the three contractile directions | 25 | 25 |
|
Platz et al. (2012) [26] | Retrospective, non-consecutive patients | PE vs. control group (age- and sex-matched subjects with no evidence of structural or valvular heart disease on echocardiography) | Global and regional RVLS | 75 | 30 |
|
Ichikawa et al. (2013) [27] | Retrospective, non-consecutive patients | PE or CPAH vs. control group (age-matched normal subjects) | Global and regional RV and LV PSS | 37 (36 CPAH) | 33 |
|
Vitarelli et al. (2014) [28] | Prospective, non-consecutive patients | Intermediate-risk PE at the onset of the acute episode and after median follow-up periods of 1 and 6 months vs. control group (sex- and age-matched healthy subjects) | RVGLS and RVFWS | 66 | 66 |
|
Khemasuwan et al. (2015) [29] | Retrospective, non-consecutive patients | Patients with PE admitted to the ICU at some point during their hospitalization | Global and regional RVLS | 110 out of a total of 211 | - | Global and regional RVLS were not associated with short-term (during hospitalization) or long-term mortality but were associated with the need of mechanical ventilation during the ICU stay |
Wright et al. (2016) [30] | Retrospective, non-consecutive patients | Non-high-risk PE vs. control group (divided into two groups, one unmatched and the other matched for age, sex, and PASP) | RVLS of the free wall | 45 | 161 with CPAH (45 matched and 116 unmatched) |
|
Ramberg et al. (2016) [31] | Retrospective, non-consecutive patients | PE vs. control group (age-matched healthy subjects) | Global and regional RVLS and RV PSS | 26 (13 had central and 13 had peripherally located PE) | 10 |
|
Dahhan et al. (2016) [32] | Retrospective, non-consecutive patients | Patients with PE followed up for 1 month after the index event | Global and regional RVLS | 69; 55 were still alive at 1 month |
- |
|
Lee et al. (2019) [33] | Prospective, non-consecutive patients | Non-high-risk PE | RVGLS and RVFWS | 144 | - |
|
Kanar et al. (2019) [34] | Prospective, non-consecutive patients | PE at the time of the index event and at 1-year follow-up | PSS of the RV free wall and Global LV PSS | 147 | − |
|
Trivedi et al. (2020) [35] | Retrospective, non-consecutive patients | Patients with PE (at the time of index event) vs. control group (sex-matched healthy subjects) | RVFWS | 84 | 66 |
|
Mazur et al. (2020) [36] | Cross-sectional, non-consecutive patients | Patients diagnosed with PE or RVMI | Global and regional RVLS | 53 PE, 23 McConnell sign + (30 patients with RVMI, 16 McConnell sign +) | - |
|
Li et al. (2022) [37] | Case-control, non-consecutive patients | PE before and after thrombolysis vs. control group (sex- and age-matched healthy subjects) | Global and regional RV PSS | 73 39—no PH 34 with PH |
40 |
|
Wilinski et al. (2023) [38] | Prospective, cross-sectional, non-consecutive patients | Patients referred for CTPA due to high clinical probability of PE. Comparison was made between those diagnosed vs. those who were not diagnosed with PE, while 30-day all-cause mortality was reported | Global and regional RVLS | 88 | 79 patients without PE |
|
Ballas et al. (2023) [13] | Prospective, consecutive patients | Patients diagnosed with PE | RVFWS | 73 | - |
|
Abbreviations: AR = apical ratio, calculated as the quotient of apical IVS strain divided by the RVFWS; AUC = area under the curve; BSA = body surface area; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CP = cor pulmonale; CPAH = chronic pulmonary artery hypertension; FAC = fractional area change; FW = free wall; HR = hazard ratio; ICU = intensive care unit; IVS = interventricular septum; LV = left ventricle; NPV = negative predictive value; PASP = pulmonary artery systolic pressure; PE = pulmonary embolism; PH = pulmonary hypertension; PSS = peak systolic strain; PSSD = peak systolic strain dyssynchrony; RV = right ventricle; RVEF = right ventricular ejection fraction; RVFWS = right ventricle free-wall strain; RVGLS = right ventricular global longitudinal strain; RVLS = right ventricle longitudinal strain; RVMI = right ventricular myocardial infarction; RVSP = right ventricular systolic pressure; sPESI = simplified pulmonary embolism severity index; TTE = transthoracic echocardiography. * = For the above comparisons, p-value was calculated as <0.05. Ɨ = Primary treatment could be thrombolysis, catheter-based pulmonary embolectomy, and/or anticoagulation therapy (they all received continuous i.v. heparin infusions). ¥ = Adverse outcomes were defined as death, cardiopulmonary resuscitation, and acute PE recurrence. ₴ = In-hospital events were defined as in-hospital PE-related death, need of additive treatments, such as thrombolysis or pulmonary artery thromboembolectomy, and need of inotropes due to unstable vital signs.